-
1
-
-
35548988945
-
-
Duvic M, Vu J. Vorinostat in cutaneous T-cell lymphoma. Drugs Today (Barc) 2007; 43: 585-599.
-
Duvic M, Vu J. Vorinostat in cutaneous T-cell lymphoma. Drugs Today (Barc) 2007; 43: 585-599.
-
-
-
-
2
-
-
34547683194
-
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
-
Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 3109-3115.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3109-3115
-
-
Olsen, E.A.1
Kim, Y.H.2
Kuzel, T.M.3
-
3
-
-
38949096781
-
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
-
Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111: 1060-1066.
-
(2008)
Blood
, vol.111
, pp. 1060-1066
-
-
Garcia-Manero, G.1
Yang, H.2
Bueso-Ramos, C.3
-
4
-
-
65549084884
-
-
http://clinicaltrials.gov/ct2/results?term=saha
-
-
-
-
5
-
-
33644836549
-
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
-
O'Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006; 24: 166-173.
-
(2006)
J Clin Oncol
, vol.24
, pp. 166-173
-
-
O'Connor, O.A.1
Heaney, M.L.2
Schwartz, L.3
-
6
-
-
39749103428
-
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
-
Richardson P, Mitsiades C, Colson K, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 2008; 49: 502-507.
-
(2008)
Leuk Lymphoma
, vol.49
, pp. 502-507
-
-
Richardson, P.1
Mitsiades, C.2
Colson, K.3
-
7
-
-
34248325147
-
Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma
-
Venturelli S, Armeanu S, Pathil A, et al. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer 2007; 109: 2132-2141.
-
(2007)
Cancer
, vol.109
, pp. 2132-2141
-
-
Venturelli, S.1
Armeanu, S.2
Pathil, A.3
-
8
-
-
43049092663
-
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
-
Crump M, Coiffier B, Jacobsen ED, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008; 19(5): 964-969.
-
(2008)
Ann Oncol
, vol.19
, Issue.5
, pp. 964-969
-
-
Crump, M.1
Coiffier, B.2
Jacobsen, E.D.3
-
9
-
-
43049091153
-
A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
-
Modesitt SC, Sill M, Hoffman JS, Bender DP. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2008; 109(2): 182-186.
-
(2008)
Gynecol Oncol
, vol.109
, Issue.2
, pp. 182-186
-
-
Modesitt, S.C.1
Sill, M.2
Hoffman, J.S.3
Bender, D.P.4
-
10
-
-
36048958965
-
Histone deacetylase inhibitors: Overview and perspectives
-
Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007; 5: 981-989.
-
(2007)
Mol Cancer Res
, vol.5
, pp. 981-989
-
-
Dokmanovic, M.1
Clarke, C.2
Marks, P.A.3
-
11
-
-
15544383986
-
A mechanistic approach to anticancer therapy: Targeting the cell cycle with histone deacetylase inhibitors
-
Mork CN, Faller DV, Spanjaard RA. A mechanistic approach to anticancer therapy: targeting the cell cycle with histone deacetylase inhibitors. Curr Pharm Des 2005; 11: 1091-1104.
-
(2005)
Curr Pharm Des
, vol.11
, pp. 1091-1104
-
-
Mork, C.N.1
Faller, D.V.2
Spanjaard, R.A.3
-
12
-
-
33845514708
-
Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?
-
Karagiannis TC, El-Osta A. Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? Leukemia 2007; 21: 61-65.
-
(2007)
Leukemia
, vol.21
, pp. 61-65
-
-
Karagiannis, T.C.1
El-Osta, A.2
-
13
-
-
34547864236
-
Histone deacetylase inhibitors: Molecular mechanisms of action
-
Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26: 5541-5552.
-
(2007)
Oncogene
, vol.26
, pp. 5541-5552
-
-
Xu, W.S.1
Parmigiani, R.B.2
Marks, P.A.3
-
14
-
-
40849151859
-
Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: Role of Annexin A1
-
Petrella A, D'Acunto CW, Rodriquez M, et al. Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: role of Annexin A1. Eur J Cancer 2008; 44(5): 740-749.
-
(2008)
Eur J Cancer
, vol.44
, Issue.5
, pp. 740-749
-
-
Petrella, A.1
D'Acunto, C.W.2
Rodriquez, M.3
-
15
-
-
34447096461
-
HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway
-
Tsapis M, Lieb M, Manzo F, et al. HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Int J Biochem Cell Biol 2007; 39: 1500-1509.
-
(2007)
Int J Biochem Cell Biol
, vol.39
, pp. 1500-1509
-
-
Tsapis, M.1
Lieb, M.2
Manzo, F.3
-
16
-
-
0035845541
-
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species
-
Ruefli AA, Ausserlechner MJ, Bernhard D, et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A 2001; 98: 10833-10838.
-
(2001)
Proc Natl Acad Sci U S A
, vol.98
, pp. 10833-10838
-
-
Ruefli, A.A.1
Ausserlechner, M.J.2
Bernhard, D.3
-
17
-
-
0038079767
-
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1
-
Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003; 63: 3637-3645.
-
(2003)
Cancer Res
, vol.63
, pp. 3637-3645
-
-
Rosato, R.R.1
Almenara, J.A.2
Grant, S.3
-
18
-
-
33845627416
-
Acetylation and histone deacetylase inhibitors in cancer
-
Kortenhorst MS, Carducci MA, Shabbeer S. Acetylation and histone deacetylase inhibitors in cancer. Cell Oncol 2006; 28: 191-222.
-
(2006)
Cell Oncol
, vol.28
, pp. 191-222
-
-
Kortenhorst, M.S.1
Carducci, M.A.2
Shabbeer, S.3
-
19
-
-
46749134822
-
BimEL-dependent apoptosis induced in peripheral blood lymphocytes with n-butyric acid is moderated by variation in expression of c-Myc and p21WAF1
-
Kalousek I, Brodska B, Otevrelova P, Röselova P. BimEL-dependent apoptosis induced in peripheral blood lymphocytes with n-butyric acid is moderated by variation in expression of c-Myc and p21WAF1. Cell Biochem Funct 2008; 26: 509-521.
-
(2008)
Cell Biochem Funct
, vol.26
, pp. 509-521
-
-
Kalousek, I.1
Brodska, B.2
Otevrelova, P.3
Röselova, P.4
-
20
-
-
34250885082
-
Actinomycin D upregulates proapoptotic protein Puma and downregulates Bcl-2 mRNA in normal peripheral blood lymphocytes
-
Kalousek I, Brodska B, Otevrelova P, Roselova P. Actinomycin D upregulates proapoptotic protein Puma and downregulates Bcl-2 mRNA in normal peripheral blood lymphocytes. Anticancer Drugs 2007; 18: 763-772.
-
(2007)
Anticancer Drugs
, vol.18
, pp. 763-772
-
-
Kalousek, I.1
Brodska, B.2
Otevrelova, P.3
Roselova, P.4
-
22
-
-
34447258837
-
Bim/Bcl-2 balance is critical for maintaining naive and memory T cell homeostasis
-
Wojciechowski S, Tripathi P, Bourdeau T, et al. Bim/Bcl-2 balance is critical for maintaining naive and memory T cell homeostasis. J Exp Med 2007; 204: 1665-1675.
-
(2007)
J Exp Med
, vol.204
, pp. 1665-1675
-
-
Wojciechowski, S.1
Tripathi, P.2
Bourdeau, T.3
-
23
-
-
5644241900
-
T-lymphocyte death during shutdown of an immune response
-
Review
-
Strasser A, Pellegrini M. T-lymphocyte death during shutdown of an immune response. Trends Immunol 2004; 25: 610-615. Review.
-
(2004)
Trends Immunol
, vol.25
, pp. 610-615
-
-
Strasser, A.1
Pellegrini, M.2
-
24
-
-
33644839920
-
Role of Bim and other Bcl-2 family members in autoimmune and degenerative diseases
-
Review
-
Hughes P, Bouillet P, Strasser A. Role of Bim and other Bcl-2 family members in autoimmune and degenerative diseases. Curr Dir Autoimmun 2006; 9: 74-94. Review.
-
(2006)
Curr Dir Autoimmun
, vol.9
, pp. 74-94
-
-
Hughes, P.1
Bouillet, P.2
Strasser, A.3
-
25
-
-
34249993174
-
SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib
-
Emanuele S, Lauricella M, Carlisi D, et al. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis 2007; 12: 1327-1338.
-
(2007)
Apoptosis
, vol.12
, pp. 1327-1338
-
-
Emanuele, S.1
Lauricella, M.2
Carlisi, D.3
-
26
-
-
23244459828
-
Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma
-
Fandy TE, Shankar S, Ross DD, Sausville E, Srivastava RK. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 2005; 7: 646-657.
-
(2005)
Neoplasia
, vol.7
, pp. 646-657
-
-
Fandy, T.E.1
Shankar, S.2
Ross, D.D.3
Sausville, E.4
Srivastava, R.K.5
-
27
-
-
24344473755
-
Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2
-
Bali P, Pranpat M, Swaby R, et al. Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2. Clin Cancer Res 2005; 11: 6382-6389.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 6382-6389
-
-
Bali, P.1
Pranpat, M.2
Swaby, R.3
-
28
-
-
38049126172
-
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma
-
Heider U, von Metzler I, Kaiser M, et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol 2008; 80: 133-142.
-
(2008)
Eur J Haematol
, vol.80
, pp. 133-142
-
-
Heider, U.1
von Metzler, I.2
Kaiser, M.3
-
29
-
-
48749090017
-
The role of oxidative stress in apoptosis induced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in human colon adenocarcinoma HT-29 cells
-
Portanova P, Russo T, Pellerito O, et al. The role of oxidative stress in apoptosis induced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in human colon adenocarcinoma HT-29 cells. Int J Oncol 2008; 33: 325-331.
-
(2008)
Int J Oncol
, vol.33
, pp. 325-331
-
-
Portanova, P.1
Russo, T.2
Pellerito, O.3
-
30
-
-
34247115447
-
c-Myc overexpression sensitizes Bim-mediated Bax activation for apoptosis induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through regulating Bcl-2/Bcl-xL expression
-
Jiang X, Tsang YH, Yu Q. c-Myc overexpression sensitizes Bim-mediated Bax activation for apoptosis induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through regulating Bcl-2/Bcl-xL expression. Int J Biochem Cell Biol 2007; 39: 1016-1025.
-
(2007)
Int J Biochem Cell Biol
, vol.39
, pp. 1016-1025
-
-
Jiang, X.1
Tsang, Y.H.2
Yu, Q.3
-
31
-
-
21844464054
-
Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis
-
Annis MG, Soucie EL, Dlugosz PJ, et al. Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis. EMBO J 2005; 24: 2096-2103.
-
(2005)
EMBO J
, vol.24
, pp. 2096-2103
-
-
Annis, M.G.1
Soucie, E.L.2
Dlugosz, P.J.3
-
32
-
-
33748343207
-
Polyamine-modulated c-Myc expression in normal intestinal epithelial cells regulates p21Cip1 transcription through a proximal promoter region
-
Liu L, Guo X, Rao JN, et al. Polyamine-modulated c-Myc expression in normal intestinal epithelial cells regulates p21Cip1 transcription through a proximal promoter region. Biochem J 2006; 398: 257-267.
-
(2006)
Biochem J
, vol.398
, pp. 257-267
-
-
Liu, L.1
Guo, X.2
Rao, J.N.3
-
33
-
-
20144384882
-
-
Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 2005; 65: 3980-3985. Review.
-
Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 2005; 65: 3980-3985. Review.
-
-
-
-
34
-
-
0036594890
-
A role of the cyclin-dependent kinase inhibitor p21 in apoptosis
-
Review
-
Gartel AL, Tyner AL. A role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002; 1: 639-649. Review.
-
(2002)
Mol Cancer Ther
, vol.1
, pp. 639-649
-
-
Gartel, A.L.1
Tyner, A.L.2
|